SK
Suresh Kumar Nandiraju
About Suresh Kumar Nandiraju
Data last updated:
Suresh Kumar Nandiraju is a Director at Clinsync Clinical Research Private Limited (since 2024), Director at Pharmarics Private Limited (since 2021) and Director at Vinda Healthcare Private Limited (since 2025), and holds 3 more current directorships. The companies operate in Pharma, Chemicals and Construction. The 3 current companies with reported revenue have a combined latest revenue of ₹15.83 Cr; the largest is Clinsync Clinical Research Private Limited at ₹15.75 Cr (FY 2025). Earlier, Suresh Kumar Nandiraju was a Director at Omnicare Drugs India Private Limited (2017–2020) and Additional Director at Benta Pharma Private Limited (2023–2024) and 4 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 26 Aug 2024 | 2011 | ₹15.75 Cr (FY 2025) | Active | |
| Director | 07 Dec 2021 | 2021 | ₹5.2 Lakh (FY 2025) | Active | |
| Director | 13 Jun 2025 | 2017 | ₹3 Lakh (FY 2024) | Active | |
| Director | 19 Jul 2025 | 2018 | Active | ||
| Designated Partner | 04 Jun 2018 | 2018 | Active | ||
| Director | 10 Aug 1999 | 1999 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 03 Apr 2017 | 2017 | ₹82.01 Cr (FY 2019) | Active | |
| Additional Director | 31 Jul 2023 | 2023 | Active | ||
| Director | 10 Oct 2017 | 2017 | ₹3.2 Lakh (FY 2025) | Active | |
| Director | 01 Dec 2017 | 2017 | ₹149 Cr (FY 2021) | Active | |
| Director | 18 Jan 2022 | 2022 | Strike Off | ||
| Director | 08 Jan 2018 | 2014 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Suresh Kumar Nandiraju
| Name | DIN | Company | Designation |
|---|---|---|---|
| Attili Venkata Satya Suresh | 03439101 | Clinsync Clinical Research Private Limited | Director |
| Koteswara Prasad Sripathipanditaradhyula | 06699849 | Clinsync Clinical Research Private Limited | Director |
| Sandhya Nandiraju | 07697975 | Clinsync Clinical Research Private Limited , Vinda Healthcare Private Limited | Whole-Time Director |
| Rajendra Hemchand Bhandari | 03084526 | Pharmarics Private Limited | Director |
| Khalil Ahmed Shaikh | 00190808 | Vidur Human Care Private Limited | Director |
| Ramakrishnan Sishtla | 07955919 | Vidur Human Care Private Limited | Director |
| Tarun Khemnani | 11187517 | Vidur Human Care Private Limited | Additional Director |
| Vamsidhar Maddipatla | 01316306 | Osr Projects Llp | Designated Partner |
| Adiseshu Radha Krishna Murthy Gollapudi | 00115648 | Ala Realtors Private Limited | Managing Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Suresh Kumar Nandiraju
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Suresh Kumar Nandiraju
Suresh Kumar Nandiraju currently holds 6 directorships: Clinsync Clinical Research Private Limited (Director, since 26 Aug 2024, revenue ₹15.75 Cr (FY 2025)); Pharmarics Private Limited (Director, since 07 Dec 2021, revenue ₹5.2 Lakh (FY 2025)); Vinda Healthcare Private Limited (Director, since 13 Jun 2025, revenue ₹3 Lakh (FY 2024)); Vidur Human Care Private Limited (Director, since 19 Jul 2025); Osr Projects Llp (Designated Partner, since 04 Jun 2018); and 1 more.
Suresh Kumar Nandiraju was first appointed on 10 Aug 1999 as Director at Ala Realtors Private Limited. The most recent appointment on record is 19 Jul 2025 at Vidur Human Care Private Limited.
The 3 current companies of Suresh Kumar Nandiraju that report revenue have a combined latest revenue of ₹15.83 Cr: Clinsync Clinical Research Private Limited ₹15.75 Cr (FY 2025); Pharmarics Private Limited ₹5.2 Lakh (FY 2025); Vinda Healthcare Private Limited ₹3 Lakh (FY 2024).
Suresh Kumar Nandiraju held 6 earlier board appointments: Omnicare Drugs India Private Limited (Director, 03 Apr 2017 to 08 Aug 2020); Benta Pharma Private Limited (Additional Director, 31 Jul 2023 to 30 Sep 2024); Neoaska Pharma Private Limited (Director, 10 Oct 2017 to 13 Jul 2023); Therapiva Private Limited (Director, 01 Dec 2017 to 08 Aug 2020); Pavo Capital India Private Limited (Director, from 18 Jan 2022); and 1 more.
The current boards of Suresh Kumar Nandiraju's companies include Attili Venkata Satya Suresh (Clinsync Clinical Research Private Limited), Koteswara Prasad Sripathipanditaradhyula (Clinsync Clinical Research Private Limited), Sandhya Nandiraju (Clinsync Clinical Research Private Limited), Rajendra Hemchand Bhandari (Pharmarics Private Limited), Khalil Ahmed Shaikh (Vidur Human Care Private Limited), Ramakrishnan Sishtla (Vidur Human Care Private Limited), among others.